CHF120.84 Novartis (NOVN.SW, SIX) pre-market 13 Mar 2026: most-active, outlook

NOVN.SW stock opens pre-market at CHF120.84 on 13 Mar 2026 and registers heavy volume, making Novartis AG one of the most-active names on the SIX exchange. The share is trading near its 50-day average of CHF119.83 and sits well above its 200-day average of CHF105.52, signalling continued investor interest. Key metrics show a trailing EPS of CHF5.56 and a PE of 21.73, while volume of 2,679,224.00 shares indicates active intraday flows that could drive short-term moves. We examine valuation, technicals, Meyka AI grading, and a forecast that frames near-term trade ideas.

Pre-market snapshot: NOVN.SW stock price, volume and movers

Novartis (NOVN.SW) is priced at CHF120.84 with a one-day change of -0.33% and a pre-market volume of 2,679,224.00 shares. The intraday range shows a low of CHF120.36 and a high of CHF121.52, while year range runs from CHF81.10 to CHF131.00. Market cap stands at CHF230.58B and average volume is 3,395,308.00, so today’s activity marks the stock as most-active on the Swiss healthcare list.

Valuation and fundamentals: NOVN.SW stock financial snapshot

Novartis posts a trailing EPS of CHF5.56 and a PE of 21.73, with revenue per share of CHF29.41 and free cash flow per share of CHF8.76. Key ratios include a price-to-sales of 5.22, price-to-book of 6.39, dividend per share CHF4.72 and dividend yield near 3.07%. The balance sheet shows a debt-to-equity of 0.80 and interest coverage of 15.13, supporting the company’s cash generation profile while keeping leverage moderate.

Technical setup and trading activity for a most-active session

Technicals show RSI at 42.70 and ADX at 30.41, indicating a strong trend but neutral momentum. Bollinger Bands middle is CHF126.39 with a lower band at CHF120.82, placing price close to the band edge and suggesting higher intraday volatility (ATR CHF2.47). Traders should watch support at CHF120.36 and resistance near CHF126.39; a break with volume could drive a decisive move.

Meyka AI rates NOVN.SW with a score out of 100

Meyka AI rates NOVN.SW with a score of 78.28 out of 100 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The proprietary grade blends growth signals (strong ROE and ROA) with valuation and leverage checks; it is informational and not investment advice.

Meyka AI’s forecast model projects near-term and medium targets

Meyka AI’s forecast model projects a quarterly target of CHF137.85 and a one-year projection of CHF117.11. Compared with the current price CHF120.84, the quarterly target implies an upside of +14.08% while the one-year projection implies a downside of -3.09%. Forecasts are model-based projections and not guarantees, and should be used alongside fundamentals and risk checks.

Analyst consensus, sector context and news flow

Third-party coverage lists Novartis as a major healthcare name on SIX with recent mentions from Reuters and market platforms; see reporting at Reuters and intraday listings at Investing.com. The Swiss healthcare sector shows modest near-term weakness versus broader markets, but Novartis’s ROE of 32.80% and FCF yield around 5.71% keep it competitive within the Drug Manufacturers – General group. Track upcoming earnings on 28 Apr 2026 and pipeline updates as catalysts.

Final Thoughts

Key takeaways for NOVN.SW stock in this pre-market, most-active session: the share trades at CHF120.84 with heavy volume that can amplify intraday moves. Fundamentals remain solid with EPS CHF5.56, PE 21.73, free cash flow per share CHF8.76, and a dividend yield near 3.07%. Meyka AI rates the stock 78.28/100 (B+, BUY) after comparing Novartis to sector peers and benchmark indices. Meyka AI’s forecast model projects a quarterly target of CHF137.85, an implied upside of +14.08% versus current price, and a one-year projection of CHF117.11 (implied -3.09%). Use those model projections cautiously: forecasts are model-based projections and not guarantees. For traders in the most-active list, watch volume-driven breaks above CHF126.39 or drops under CHF120.36; position size accordingly and account for pipeline and earnings risks. For longer-term investors, the blend of cash flow, dividend yield, and R&D intensity supports a constructive view but valuation (price-to-book 6.39) suggests limited margin for multiple expansion without growth catalysts. See the Meyka NOVN.SW page for real-time updates and tools Meyka NOVN.SW.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.